SPOTLIGHT: Me-too drugs now a tough sell


One of pharma's business strategies may be nearing a dead end. As drug pipelines began to trickle instead of flow, drugmakers turned to tweaking existing drugs as a way to get new products onto the market. But health insurers, who've become ever more vigilant about pushing lower-cost drugs, are getting skeptical, Dow Jones reports. So-called "me too" drugs are about to face a tougher market. Report

Suggested Articles

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.